There was close agreement and no significant differences between m-WOMAC and p-WOMAC scores. This study confirms the validity, reliability, and responsiveness of the Exco InTouch-engineered, Java-based m-WOMAC Index application. EDC with the m-WOMAC Index provides unique opportunities for using quantitative measurement in clinical research and practice.

Objective OA pathogenesis includes both mechanical and inflammatory features. Studies have implicated synovial fluid urate (UA) as a potential OA biomarker, possibly reflecting chondrocyte damage. Whether serum urate (sUA) levels reflect/contribute to OA is unknown. We investigated whether sUA predicts OA progression in a non-gout knee OA population. Methods Eighty-eight subjects with medial knee OA (BMI <33) but without gout were included. Baseline sUA was measured in previously banked serum. At 0 and 24 months, subjects underwent standardized weight-bearing fixed-flexion posteroanterior knee radiographs to determine joint space width (JSW) and Kellgren-Lawrence (KL) grades. Joint space narrowing (JSN) was determined as JSW change from 0 to 24 months. Twenty-seven subjects underwent baseline contrast-enhanced 3T knee MRI for synovial volume (SV) assessment. Results sUA correlated with JSN in both univariate (r=0.40, p≤0.01) and multivariate analyses (r=0.28, p=0.01). There was a significant difference in mean JSN after dichotomizing at sUA of 6.8 mg/dL, the solubility point for serum urate, even after adjustment (JSN of 0.90 mm for sUA≥6.8; JSN of 0.31 mm for sUA<6.8, p<0.01). Baseline sUA distinguished progressors (JSN>0.2mm) and fast progressors (JSN>0.5mm) from nonprogressors (JSN≤0.0mm) in multivariate analyses (area under the receiver operating characteristic curve 0.63, p=0.03; AUC 0.62, p=0.05, respectively). sUA correlated with SV (r=0.44, p<0.01), a possible marker of JSN, though this correlation did not persist after controlling for age, gender and BMI (r=0.13, p=0.56). Conclusions In non-gout patients with knee OA, sUA predicted future JSN and may serve as a biomarker for OA progression.

These data support the feasibility of repeated independent remote data capture using the m-WOMAC NRS3.1 Index.

Patient reported ratings indicated the m-WOMAC application performed well on all three phones. EDC provides unique opportunities for using quantitative measurement in both clinical practice and research.

Background: The t:slim X2 with Control-IQ technology (“Control-IQ”) is an advanced hybrid closed-looped system. This analysis evaluated glycemic outcomes in Control-IQ users by payer type using Healthcare Effectiveness Data and Information Set (HEDIS) quality thresholds. HEDIS is used by &gt;90% of health plans to measure performance and includes a metric to identify A1c control (&lt;8.0%) and poor control (&gt;9.0%). Glucose management indicator (GMI) is a recognized surrogate for A1c when sufficient data are provided (≥14 days, 70% CGM use). Methods: We retrospectively analyzed glycemic data for individuals with type 1 diabetes from 1/1/20 to 3/4/23 who used Control-IQ for ≥1 year (with ≥70% of CGM use in final 3 months) and had a recorded baseline A1c prior to Control-IQ initiation. Results were stratified by payer type, prior therapy, and baseline A1c. GMI was calculated for last 3 months and compared to baseline A1c. Results: Analysis included 20,319 users, with 42% (n= 8,493) on multiple daily injections (MDI) and 58% (n=11,826) on pump therapy at baseline. Control-IQ use significantly improved glycemic outcomes and mean HEDIS thresholds were achieved for all payer types and strata (table). Conclusion: Control-IQ use improved HEDIS A1c (GMI) outcomes across all payer types, with the largest glycemic improvement seen in those with the highest A1c at baseline and for prior MDI users. Disclosure B. V. Patel: Employee; Tandem Diabetes Care, Inc. Stock/Shareholder; Tandem Diabetes Care, Inc. G. Alencar: Employee; Tandem Diabetes Care, Inc. S. M. Wang: Employee; Tandem Diabetes Care, Inc. Stock/Shareholder; Tandem Diabetes Care, Inc. S. Leas: Employee; Tandem Diabetes Care, Inc. L. H. Messer: Employee; Tandem Diabetes Care, Inc. Consultant; Dexcom, Inc. Advisory Panel; Lilly. Consultant; Capillary Biomedical, Inc. Research Support; Beta Bionics, Inc., Medtronic, Insulet Corporation. J. E. Pinsker: Employee; Tandem Diabetes Care, Inc.